Results 251 to 260 of about 4,769,883 (431)

CDK5 interacts with MST2 and modulates the Hippo signalling pathway

open access: yesFEBS Open Bio, Volume 15, Issue 4, Page 647-660, April 2025.
By using a yeast‐two‐hybrid system, immune precipitation and a proteomics approach, we identify a novel interaction between CDK5 and MST2, which modulates the mechano‐sensitive Hippo signalling pathway in a liver tumour cell line. MST2 (STK3) is a major upstream kinase in the Hippo signalling pathway, an evolutionary conserved pathway in regulation of ...
Mehak Passi   +5 more
wiley   +1 more source

CD44v, S1PR1, HER3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb

open access: yesFEBS Open Bio, Volume 15, Issue 5, Page 867-884, May 2025.
Novel mAbs could detect cancer‐associated membrane proteins on various type of pancreatic ductal adenocarcinomas (PDAC) by flow cytometry with viable PDAC cells and by immunohistochemistry with PDAC tissues. Results of protein expression were substantiated by mRNA expression by The Cancer Genome Atlas.
Takashi Nakano   +16 more
wiley   +1 more source

Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

open access: yesAmerican Journal of Pathology, 2012
B. Hinz   +8 more
semanticscholar   +1 more source

Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation

open access: yesFEBS Open Bio, Volume 15, Issue 5, Page 836-855, May 2025.
Osimertinib reduces angiogenesis and PDL1 expression in in ovo tumors, transforming them into ‘cold tumors’ with lower immune activity. Anatomopathological and transcriptomic analyses highlight its therapeutic impact on tumor biology. This study underscores osimertinib's potential to reshape the tumor microenvironment and provides insights into its ...
David Barthélémy   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy